Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Imunon (0HUZ) Price & Analysis

0HUZ Stock Chart & Stats

$11.48$0.00(0.00%)
At close: 4:00 PM EDT
$10$12.54 Nov18 Nov2 Dec16 Dec30 Dec13 Jan28 Jan
Day’s Range
$11.48 - $11.48
52-Week Range
$11.48 - $11.48
Previous Close
$11.48
Volume
0
Average Volume (3M)
0
Market Cap
$5.11M
Enterprise Value
$10.29M
Total Cash (Recent Filing)
$6.86M
Total Debt (Recent Filing)
$7.85M
Price to Earnings (P/E)
―
Beta
-0.02
Next Earnings
Nov 16, 2026
EPS Estimate
-0.55
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy

The reported overall-survival gains provide meaningful clinical validation for IMUNON-001 and could support differentiation in ovarian cancer if confirmed. Durable efficacy evidence may improve the program’s partnering, regulatory, and adoption potential as later-stage data mature.

Phase III Execution

Enrollment materially ahead of plan indicates that the pivotal program is attracting patients and that site activation is functioning effectively. Sustained execution can shorten operational bottlenecks, improve trial predictability, and accelerate the path toward confirmatory clinical evidence.

Strategic Focus

Divesting a legacy asset can simplify the portfolio and concentrate management attention and capital on IMNN-001, the company’s principal value-creating program. Potential milestones, royalties, and an equity stake also preserve upside if the buyer successfully advances ThermoDox.

Bears Say

No Meaningful Revenue

The absence of a meaningful revenue base leaves the company dependent on clinical progress and external financing rather than internally generated commercial cash flow. Persistent losses also reduce earnings visibility and make the business more vulnerable if development milestones are delayed.

Cash Burn And Funding Dependence

Continued operating cash consumption, together with a sharply higher TTM outflow, creates sustained financing pressure while Phase III spending increases. The stated runway only extends through year-end 2026, so future execution depends on raising additional capital on acceptable terms.

Clinical Statistical Uncertainty

Encouraging MRD signals may not translate into reliable evidence because the study’s small, exploratory design limits statistical certainty. Until larger confirmatory datasets are available, this uncertainty can constrain confidence in biomarker performance, regulatory value, and eventual clinical adoption.

Imunon News

0HUZ FAQ

What was Imunon’s price range in the past 12 months?
Imunon lowest share price was $11.48 and its highest was $11.48 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $5.11M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Nov 16, 2026 which is in 15 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Aug 11, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.868 by $0.328.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon pays a Notavailable dividend of $0.182 which represents an annual dividend yield of ―. See more information on Imunon dividends here
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.55.
How many shares outstanding does Imunon have?
Imunon has 5,611,403 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.868. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in GB:0HUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology